Stefan W Toennes et al.
Journal of pharmaceutical and biomedical analysis, 140, 215-222 (2017-04-04)
Each year, synthetic cannabinoids are occurring in high numbers in the illicit drug market, but data on their pharmacology and toxicology are scarcely available. Therefore, a pilot study was performed to assess adverse effects of JWH-018, which is one of...
Marek Bednarski et al.
Archiv der Pharmazie, 349(3), 211-223 (2016-02-09)
β-Adrenergic receptor antagonists are important therapeutics for the treatment of cardiovascular disorders. In the group of β-blockers, much attention is being paid to the third-generation drugs that possess important ancillary properties besides inhibiting β-adrenoceptors. Vasodilating activity of these drugs is...
Shalenie P den Braver-Sewradj et al.
Current drug metabolism, 19(4), 370-381 (2018-01-11)
Inter-individual variability in hepatic drug metabolizing enzyme (DME) activity is a major contributor to heterogeneity in drug clearance and safety. Accurate data on expression levels and activities of DMEs is an important prerequisite for in vitro-in vivo extrapolation and in...
Alexandra M Adams et al.
Metabolic engineering, 56, 111-119 (2019-09-25)
Psilocybin, the prodrug of the psychoactive molecule psilocin, has demonstrated promising results in clinical trials for the treatment of addiction, depression, and post-traumatic stress disorder. The development of a psilocybin production platform in a highly engineerable microbe could lead to...
Gavin Carr et al.
Journal of medicinal chemistry, 51(9), 2634-2637 (2008-04-09)
Synthetic analogues of the sponge natural product exiguamine A (3) have been prepared and evaluated for their ability to inhibit indoleamine 2,3-dioxygenase in vitro.